Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Navigating the barriers to successful market access The steps required for successful market access.
Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
Views & Analysis What is ‘affordable’? The reality of the PPRS PPRS impact: has it kept the branded medicines bill within affordable limits?
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
